Vivo Capital completed a $50m investment in Scientia Vascular.

Vivo Capital, a global healthcare investment firm, completed a $50m investment in Scientia Vascular, a rapidly growing commercial company focused on helping save patients’ lives with a suite of interventional medical devices. “Neurovascular surgery and in particular, stroke treatment, is one of the most exciting segments in the medical device sector. We have been searching for a platform medical device company in the neurovascular surgery space for a long time. We are honored to partner with John Lippert, a pioneer in the field, and the veteran team he has assembled at Scientia Vascular,” Joseph Siletto, Vivo Capital Managing Director.